Drug Type Small molecule drug |
Synonyms VC 004, VC004 |
Target |
Action antagonists |
Mechanism TrkA antagonists(Nerve growth factor receptor Trk-A antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Malignant Solid Neoplasm | Phase 3 | China | 17 Mar 2025 | |
NTRK fusion-positive solid tumors | Phase 3 | China | 20 Feb 2025 | |
Brain metastases | Phase 2 | China | 20 Nov 2020 | |
Glioblastoma | Phase 2 | China | 20 Nov 2020 | |
Metastatic Solid Tumor | Phase 2 | China | 20 Nov 2020 | |
Salivary Gland Neoplasms | Phase 2 | China | 20 Nov 2020 | |
Soft Tissue Sarcoma | Phase 2 | China | 20 Nov 2020 | |
Thyroid Cancer | Phase 2 | China | 20 Nov 2020 | |
Cancer Pain | IND Approval | China | 16 Aug 2023 | |
inflammatory dermatosis | IND Approval | China | 22 May 2023 |
Phase 1/2 | 51 | zyebzcwugr(jnvdfgnulj) = ≥20% fwysvwqnsx (gqzglopgxs ) View more | Positive | 24 May 2024 |